Mesalamine suppresses the expression of TC22, a novel tropomyosin isoform associated with colonic neoplasia

Molecular Pharmacology

Volumn 76, Issue 1, 2009, Pages 183-191

  Das, Koushik K ^a   Bajpai, Manisha ^a   Kong, Yingxin ^a   Liu, Jianying ^a   Geng, Xin ^a   Das, Kiron M ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA1 INTEGRIN; ALPHA3 INTEGRIN; DEATH RECEPTOR 3; GELATINASE A; INTERSTITIAL COLLAGENASE; MESALAZINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; SALAZOSULFAPYRIDINE; SMALL INTERFERING RNA; SOMATOMEDIN C; SULFAPYRIDINE; SULINDAC; TC22 PROTEIN; TROPOMYOSIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL ADHESION; CHEMOPROPHYLAXIS; COLON CANCER; COLON MUCOSA; COLON TUMOR; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; EPITHELIUM CELL; FLUORESCENCE ACTIVATED CELL SORTING; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOLECULAR CLONING; MOLECULAR MECHANICS; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN VARIANT; REAL TIME POLYMERASE CHAIN REACTION; RETREATMENT; TISSUE REGENERATION;

ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MESALAMINE; PPAR GAMMA; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SULFASALAZINE; TROPOMYOSIN;

EID: 67649878537     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.056028     Document Type: Article

References (39)

1. Allgayer H (2003) Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther 18 (Suppl 2):10-14. (Pubitemid 37174711)
2. Bus PJ, Nagtegaal ID, Verspaget HW, Lamers CB, Geldof H, Van Krieken JH, and Griffioen G (1999) Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment Pharmacol Ther 13:1397-1402.
3. Croog VJ, Ullman TA, and Itzkowitz SH (2003) Chemoprevention of colorectal cancer in ulcerative colitis. Int J Colorectal Dis 18:392-400. (Pubitemid 37062729)
4. Das KM and Dubin R (1976) Clinical pharmacokinetics of sulfasalazine. Clin Pharmacokinet 1:406-425.
5. Das KM, Eastwood MA, McManus JP, and SircusW(1973) Adverse reactions during salicylazosulfapyridine therapy and the relationship with drug metabolism and acetylator phenotype. N Engl J Med 289:491-495.
6. Davis AE, Patterson F, and Crouch R (1992) The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model. Br J Cancer 66:777-780.
7. Dubuquoy L, Dharancy S, Nutten S, Pettersson S, Auwerx J, and Desreumaux P (2002) Role of peroxisome proliferators-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet 360:1410-1418. (Pubitemid 35341309)
8. Dubuquoy L, Jansson EA, Deeb S, Rakotobe S, Karoui M, Colombel JF, Auwerx J, Pettersson S, and Desreumaux P (2003) Impaired expression of peroxisome proliferators- activated receptor γ in ulcerative colitis. Gastroenterology 124:1265-1276. (Pubitemid 36531802)
9. Eaden JA, Abrams KR, and Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48:526-535. (Pubitemid 32234798)
10. Ekbom A, Helmick C, Zack M, and Adami HO (1990) Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323:1228-1233. (Pubitemid 20366527)
11. Frieri G, Pimpo MT, Palumbo GC, Onori L, Viscido A, Latella G, Galletti B, Pantaleoni GC, and Caprilli R (1999) Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment. Aliment Pharmacol Ther 13:1413-1417. (Pubitemid 29516252)
12. Geng X, Biancone L, Dai HH, Lin JJ, Yoshizaki N, Dasgupta A, Pallone F, and Das KM (1998) Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology 114:912-922. (Pubitemid 28217556)
13. Geng X, Yingxin K, Sefah A, Papper M, and Das KM (2007) Expression of a novel colon cancer marker, TC22, in ulcerative colitis mucosa: a possible molecular tool for screening (Abstract). Gastroenterology 132:A634.
14. Girnun GD and Spiegelman BM (2003) PPARγ ligands: taking part in chemoprevention. Gastroenterology 124:564-567. (Pubitemid 36169271)
15. Han S and Roman J (2006) Rosiglitazone suppresses human lung carcinoma cell growth through PPAR-independent signal pathways. Mol Cancer Ther 5:430-437.
16. Harris J, Archampong EQ, and Clark CG (1972) The effect of Salazopyrin on water and electrolyte transport in the human colon measured in vivo and in vitro. Gut 13:855.
17. Kane SV, Cohen RD, Aikens JE, and Hanauer SB (2001) Prevalence of Nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 96:2929-2933. (Pubitemid 32959535)
18. Lauritsen K, Hansen J, Ryde M, and Rask-Madsen J (1984) Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Gastroenterology 86:1496-1500. (Pubitemid 14147943)
19. Lewis JD, Lichtenstein GR, Deren JJ, Sands BE, Hanauer SB, Katz JA, Lashner B, Present DH, Chuai S, Ellenberg JH, et al. (2008) Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 134:688-695. (Pubitemid 351312727)
20. Lewis JD, Lichtenstein GR, Stein RB, Deren JJ, Judge TA, Fogt F, Furth EE, Demissie EJ, Hurd LB, Su CG, et al. (2001) An open label trial of the PPARγligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 96:3323-3328. (Pubitemid 34016655)
21. Lin JL, Geng X, Bhattacharya SD, Yu JR, Reiter RS, Sastri B, Glazier KD, Mirza ZK, Wang KK, Amenta PS, et al. (2002) Isolation and sequencing of a novel tropomyosin isoform preferentially associated with colon cancer. Gastroenterology 123: 152-162. (Pubitemid 34747536)
22. Matula S, Croog V, Itzkowitz S, Harpaz N, Bodian C, Hossain S, and Ullman T (2005) Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol 3:1015-1021. (Pubitemid 41415750)
23. Moody GA, Jayanthi V, Probert CS, Mac Kay H, and Mayberry JF (1996) Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 8:1179-1183. (Pubitemid 26413548)
24. Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T, Matsuhashi N, Kadowaki T, Ochiai M, Sekihara H, et al. (2003) Peroxisome proliferator activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 124:361-367. (Pubitemid 36169253)
25. Peskar BM, Dreyling KW, May B, Schaarschmidt K, and Goebell H (1987) Possible mode of action of 5-aminosalicylic acid. Dig Dis Sci 32:51S-56S. (Pubitemid 18123619)
26. Reinacher-Schick A, Schoeneck A, Graeven U, Schwarte-Waldhoff I, and Schmiegel W (2003) Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis 24:443-451. (Pubitemid 36432639)
27. Reinacher-Schick A, Seidensticker F, Petrasch S, Reiser M, Philippou S, Theegarten D, Freitag G, and Schmiegel W (2000) Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy 32:245-254. (Pubitemid 30103489)
28. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, et al. (2005) Intestinal anti-inflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferators-activated receptor-γ. J Exp Med 201:1205-1215. (Pubitemid 40629065)
29. Rubin DT, LoSavio A, Yadron N, Huo D, and Hanauer SB (2006) Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol 4:1346-1350. (Pubitemid 44716744)
30. Rubinstein A, Das KM, Melamed J, and Murphy RA (1978) Comparative analysis of systemic immunological parameters in ulcerative colitis and idiopathic proctitis: Effects of sulfasalazine in vitro and in vivo. Clin Exp Immunol 33:217-224. (Pubitemid 9024297)
31. Shanahan F, Niederlehner A, MacDermott RP, Stenson WF, Kane MG, and Targan S (1986) Inhibition of cytotoxicity by sulfasalazine. II. Sulfasalazine and sulfapyridine inhibit different stages of the NK and NKCF lytic process. Immunopharmacology 11:111-118.
32. Sharon P, Ligumsky M, Rachmilewitz D, and Zor U (1978) Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 75:638-640.
33. Shiff SJ, Qiao L, Tsai LL, and Rigas B (1995) Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 96:491-503.
34. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, and Wu GD (1999) A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 104:383-389. (Pubitemid 29534322)
35. Tanaka T, Kohno H, Yoshitani S, Takashima S, Okumura A, Murakami A, and HosokawaM(2001) Ligands for peroxisome proliferators activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 61:2424-2428. (Pubitemid 32685818)
36. Taniguchi M, Geng X, Glazier KD, Dasgupta A, Lin JJ, and Das KM (2001) Cellular immune response against tropomyosin isoform 5 in ulcerative colitis. Clin Immunol 101:289-295. (Pubitemid 33145012)
37. Velayos FS, Terdiman JP, and Walsh JM (2005) Effect of 5-Aminosalicylate use on colorectal cancer and dysplasia risk: A systematic review and metaanalysis of observational studies. Am J Gastroenterol 100:1345-1353. (Pubitemid 40904360)
38. West B, Lendrum R, Hill MJ, and Walker G (1974) Effects of sulphasalazine (Salazopyrin) on faecal flora in patients with inflammatory bowel disease. Gut 15:960-965.
39. Wu GD (2003) Is there a role for PPARγ in IBD? Yes, no, maybe. Gastroenterology 124:1538-1542. (Pubitemid 36531826)